Author: Ramin Tadayoni (France)
Co-authors: David Brown, Sebastian Wolf, Francesco Bandello, Andres Emanuelli, Jose Juan Escobar Barranco, Joao Figueira
Purpose
To present the 52-week results from KESTREL and KITE, two prospective Phase III studies evaluating the efficacy and safety of brolucizumab versus aflibercept for the treatment of patients with visual impairment due to diabetic macular edema (DME).
Setting/Venue
Patients were enrolled from 36 countries, across 197 sites.
Methods
KESTREL (NCT03481634) and KITE (NCT03481660) are two, 2-year, ongoing, double-masked, randomized, active-controlled, multicenter studies. Adults (≥18 years of age) with type 1 or type 2 diabetes mellitus, visual impairment due to DME with a best-corrected visual acuity (BCVA) score between 78 to 23 ETDRS letters, and DME involving the center of the macula with a central subfield thickness (CSFT) ≥320μm on SD-OCT in the study eye at screening were included. In KESTREL, patients were randomized 1:1:1 to brolucizumab 3 mg, brolucizumab 6 mg or aflibercept 2mg; in KITE, patients were randomized 1:1 to brolucizumab 6 mg or aflibercept 2 mg. The brolucizumab groups received 5 loading doses every 6 weeks (q6w) followed by q12w dosing in the first year, with an option to adjust to q8w if disease activity is identified at those pre-specified visits. The aflibercept group received 5 loading doses monthly followed by a fixed q8w dosing. The primary endpoint was the change from baseline in BCVA at Week 52; secondary endpoints included the proportion of brolucizumab patients maintained at q12w dosing up to Week 52 and the change from baseline in CSFT. -
Results
In both studies, the primary objective was met with brolucizumab 6mg achieving non-inferiority (margin of 4 letters) to aflibercept in change of BCVA from baseline at Week 52 (KESTREL, letters: brolucizumab 6mg +9.2 vs aflibercept +10.5, mean difference –1.3 [95% CI,–2.9, 0.3], p<0.001; KITE, letters: brolucizumab 6mg +10.6 vs aflibercept +9.4, mean difference +1.2 [95% CI,–0.6, 3.1], p<0.001). Brolucizumab 3mg did not demonstrate non-inferiority in BCVA versus aflibercept in KESTREL. More than 50% of brolucizumab 6mg patients were maintained on a q12w dosing interval through Week 52, immediately after the loading phase. For the change of CSFT from baseline over the period Week 40 through Week 52, significant improvements were achieved with brolucizumab 6mg in both studies; in KITE, brolucizumab 6mg showed superior improvements in change of CSFT over the period Week 40 through Week 52 versus aflibercept (p=0.001). At Week 52, more patients treated with brolucizumab 6mg achieved a CSFT <280µm than with aflibercept (KESTREL: 54.0% versus 40.1%; KITE: 57.5% versus 41.4%). Fewer brolucizumab 6mg patients had SRF and/or IRF versus aflibercept at Week 52 (KESTREL: 60.3% versus 73.3%; KITE: 54.2% versus 72.9%). Brolucizumab demonstrated an overall well-tolerated safety profile.
Conlusions
Results from the KESTREL and KITE studies show that brolucizumab 6 mg achieved robust vision gains and improved anatomical outcomes with more than 50% of DME patients maintained on a q12w treatment interval after loading through Week 52, and demonstrated an overall well-tolerated safety profile.
Financial Disclosure
Advisor: Alcon, Allergan, Bayer, Genentech, Novartis, Oculis, Roche, Thea, Zeiss
Comments
Additional co-authors: 7. Vishali Gupta - Advanced Eye Center, Post Graduate Institute of Medical Education and Research, Chandigarh, India 8. Nor Fariza Ngah - Hospital Shah Alam, Selangor, Malaysia 9. Gerald Liew - Centre for Vision Research, Westmead Institute for Medical Research, University of Sydney, Sydney, Australia 10. Raman Tuli - Department of Ophthalmology, University of Ottawa, Ottawa, Canada and The Retina Centre of Ottawa, Canada 11. Lixin Wang Wang - Novartis Pharma AG, Basel, Switzerland 12. Ying Wang Wang - Novartis Pharma AG, Basel, Switzerland 13. Emmanuel Bouillaud - Novartis Pharma AG, Basel, Switzerland 14. Eric Souied - Department of Ophthalmology, Hopital Intercommunal de Creteil, Créteil, France 15. Justus Garweg - Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland and Berner Augenklinik am Lindenhofspital and Swiss Eye Institute, Bern, Switzerland